Pyridoxine-dependent seizures and cognition in adulthood

Kathleen Baynes1, Sarah Tomaszewski Farias, Sidney M Gospe

  • 1Department of Neurology, Center for Neurosciences, University of California, Davis, CA, USA.

Insights

Pyridoxine-dependent epilepsy, a rare neonatal seizure disorder, was treated early in this patient. Despite prompt intervention, long-term evaluation revealed mild intellectual disability and specific cognitive deficits.

Area of Science:

  • Neurology
  • Genetics
  • Developmental Pediatrics

Background:

  • Pyridoxine-dependent epilepsy (PDE) is a rare inherited metabolic disorder causing intractable seizures in newborns.
  • It results from a deficiency in the enzyme ALDH7A1, leading to accumulation of toxic metabolites.
  • Early diagnosis and treatment with pyridoxine (vitamin B6) are crucial for seizure control.

Observation:

  • A male infant presented with neonatal onset seizures and was treated with pyridoxine within 8 hours of birth.
  • Neuropsychological evaluation at age 37 and MRI at age 31 were performed.
  • The patient exhibited a significant Performance IQ advantage over Verbal IQ, with impaired expressive language skills.

Findings:

  • The patient's Full-Scale IQ was 71, Verbal IQ was 64, and Performance IQ was 85.
  • MRI revealed characteristic thinning of the posterior corpus callosum.
  • Despite early and continuous pyridoxine treatment, the patient developed mild mental retardation.

Implications:

  • This case highlights that even with early treatment, individuals with pyridoxine-dependent epilepsy may experience cognitive deficits.
  • The consistent findings across cases suggest a shared underlying mechanism for structural brain changes and cognitive profiles in PDE.
  • Further research into the neurobiological impact of ALDH7A1 deficiency is warranted to improve long-term outcomes.

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...